Cost-Utility Analysis of Universal Lynch Syndrome Screening among Colorectal Cancer Patients in a Low-Middle-Income Country
Yonsei Medical Journal · 2025
DOI: 10.3349/ymj.2024.0352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Yonsei Medical Journal, 2025. Verfasst von Cong Bang Huynh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endoscopy, University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Cost-Benefit Analysis, Colorectal Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea International Cooperation Agency.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Lynch syndrome (LS) is the most common hereditary cause of colorectal cancer (CRC). While screening for LS is recommended in Western countries, limited economic evaluations exist in lower-middle-income countries such as Vietnam, where CRC incidence is rapidly increasing. This study assessed the cost-utility of universal LS screening in Vietnam from the healthcare system's perspective. MATERIALS AND METHODS: We developed a decision-analytic model integrating decision trees and Markov models to compare the cost-effectiveness of three strategies: no screening, universal immunohistochemistry (IHC) followed by germline testing, and germline testing without prior tumor analysis. Cost data were derived from Vietnamese healthcare sources, and outcomes were measured in quality-adjusted life years (QALYs). To assess parameter uncertainty, we conducted both one-way sensitivity analysis and probabilistic sensitivity analysis. RESULTS: Universal LS screening was found to be highly cost-effective. Universal germline testing identified the most LS CRC patients (n=742), followed by universal IHC testing (n=646). Compared to no screening, the incremental cost-effectiveness ratios were 47615038 VND/QALY (1904 USD/QALY) for germline testing and 126095537 VND/QALY (5043 USD/QALY) for IHC. Key influential variables included LS prevalence, CRC risk in LS carriers, the proportion of relatives with LS accepting increased surveillance, the acceptance rate of LS testing among relatives, and germline testing cost. CONCLUSION: All LS screening strategies for CRC patients are cost-effective within the Vietnamese health system, with germline testing being the most favorable. These findings support the inclusion of LS screening in health policies, even in resource-limited settings such as Vietnam.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endoscopy, University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam.
- Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Department of Biochemistry, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
- Department of Surgery, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. viet.uv@umc.edu.vn.
ORCID-Profile: Cong Bang Huynh, Changsoo Kim, Nien Vinh Lam, Van Viet Ung
Förderung
- Korea International Cooperation Agency
Zitieren
APA
Huynh, C. B., Kim, C., Lam, N. V., & Ung, V. V. (2025). Cost-Utility Analysis of Universal Lynch Syndrome Screening among Colorectal Cancer Patients in a Low-Middle-Income Country. Yonsei Medical Journal. https://doi.org/10.3349/ymj.2024.0352
Vancouver
Huynh CB, Kim C, Lam NV, Ung VV. Cost-Utility Analysis of Universal Lynch Syndrome Screening among Colorectal Cancer Patients in a Low-Middle-Income Country. Yonsei Medical Journal. 2025. doi:10.3349/ymj.2024.0352
BibTeX
@article{Huynh2025,
author = {Huynh, Cong Bang and Kim, Changsoo and Lam, Nien Vinh and Ung, Van Viet},
title = {Cost-Utility Analysis of Universal Lynch Syndrome Screening among Colorectal Cancer Patients in a Low-Middle-Income Country},
journal = {Yonsei Medical Journal},
year = {2025},
doi = {10.3349/ymj.2024.0352}
}
EUVIMED